Ocular Pain - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：51頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Ocular Pain - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H1 2014’, provides an overview of the Ocular Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H1 2014’, provides an overview of the Ocular Pain’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ocular Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ocular Pain Overview 6
Therapeutics Development 7
Pipeline Products for Ocular Pain - Overview 7
Pipeline Products for Ocular Pain - Comparative Analysis 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
Sylentis S.A. 14
Bayer AG 15
InSite Vision Incorporated 16
Reata Pharmaceuticals, Inc. 17
Kala Pharmaceuticals, Inc. 18
Ocular Pain - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bromfenac sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
mapracorat - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SYL-1001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
loteprednol etabonate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RTA-408 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Ocular Pain - Recent Pipeline Updates 36
Ocular Pain - Dormant Projects 42
Ocular Pain - Product Development Milestones 43
Featured News & Press Releases 43
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 43
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 43
May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations 44
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 46
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 46
Apr 17, 2013: Bausch + Lomb Launches Prolensa At ASCRS Annual Meeting 2013 47
Apr 17, 2013: Bausch + Lomb Highlights Data On Lotemax At ASCRS Annual Meeting 2013 47
Apr 08, 2013: Bausch + Lomb Receives FDA Approval For Prolensa 0.07% 47
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 48
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Ocular Pain, H1 2014 7
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Ocular Pain - Pipeline by Sylentis S.A., H1 2014 14
Ocular Pain - Pipeline by Bayer AG, H1 2014 15
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2014 16
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 17
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2014 36
Ocular Pain - Dormant Projects, H1 2014 42
List of Figures
Number of Products under Development for Ocular Pain, H1 2014 7
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ocular Pain Overview 6
Therapeutics Development 7
Pipeline Products for Ocular Pain - Overview 7
Pipeline Products for Ocular Pain - Comparative Analysis 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
Sylentis S.A. 14
Bayer AG 15
InSite Vision Incorporated 16
Reata Pharmaceuticals, Inc. 17
Kala Pharmaceuticals, Inc. 18
Ocular Pain - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bromfenac sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
mapracorat - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SYL-1001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
loteprednol etabonate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RTA-408 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Ocular Pain - Recent Pipeline Updates 36
Ocular Pain - Dormant Projects 42
Ocular Pain - Product Development Milestones 43
Featured News & Press Releases 43
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 43
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 43
May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations 44
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 46
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 46
Apr 17, 2013: Bausch + Lomb Launches Prolensa At ASCRS Annual Meeting 2013 47
Apr 17, 2013: Bausch + Lomb Highlights Data On Lotemax At ASCRS Annual Meeting 2013 47
Apr 08, 2013: Bausch + Lomb Receives FDA Approval For Prolensa 0.07% 47
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 48
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51
List of Tables
Number of Products under Development for Ocular Pain, H1 2014 7
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Ocular Pain - Pipeline by Sylentis S.A., H1 2014 14
Ocular Pain - Pipeline by Bayer AG, H1 2014 15
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2014 16
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 17
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2014 36
Ocular Pain - Dormant Projects, H1 2014 42
List of Figures
Number of Products under Development for Ocular Pain, H1 2014 7
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
